欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Dxd_1599440-33-1_产品详情
1599440-33-1
  • names:

    Dxd

  • CAS号:

    1599440-33-1

    MDL Number:
  • MF(分子式): C26H24FN3O6 MW(分子量): 493.48
  • EINECS:NA Reaxys Number:
  • Pubchem ID:117888634 Brand:BIOFOUNT
Dxd
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM000905-100mg 1g 98.2% ¥ 0.00 ¥ 0.00 2-3天
- +
¥ 0.00
YZM000905-50mg 50mg 98.2% ¥ 0.00 ¥ 0.00 2-3天
- +
¥ 0.00
YZM000905-5mg 5mg 98.2% ¥ 17550.00 ¥ 17550.00 1250 2-3天
- +
¥ 0.00
YZM000905-1mg 1mg 98.2% ¥ 6450.00 ¥ 6450.00 6450 1-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名 Exatecan derivative for ADC
英文别名 UNII-OQM5SD32BQ;OQM5SD32BQ;Dxd;SCHEMBL16485136;N-[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]-2-hydroxyacetamide
CAS号 1599440-33-1
Inchi InChI=1S/C26H24FN3O6/c1-3-26(35)15-6-19-23-13(8-30(19)24(33)14(15)10-36-25(26)34)22-17(28-20(32)9-31)5-4-12-11(2)16(27)7-18(29-23)21(12)22/h6-7,17,31,35H,3-5,8-10H2,1-2H3,(H,28,32)/t17-,26-/m0/s1
InchiKey PLXLYXLUCNZSAA-QLXKLKPCSA-N
分子式 Formula C26H24FN3O6
分子量 Molecular Weight 493.48
溶解度Solubility 生物体外In Vitro:DMSO溶解度50 mg/mL(101.32 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble)
性状 Solid powder
储藏条件 Storage conditions 0 - 4 ℃ for short term 短期保存(days to weeks), or -20 C for long term (months).
产品说明 DXD是Exatecan衍生物和拓扑异构酶I抑制剂。 DXD可用于制备抗体药物偶联物,例如曲妥珠单抗Deruxtecan(DS-8201a)。
IntroductionDxd (Exatecan derivative for ADC) is a potentDNA topoisomerase Iinhibitor, with anIC50of 0.31 μM, used as a conjugated drug of HER2argeting ADC (DS201a).
Application1DXD is an Exatecan derivative and topoisomerase I inhibitor. DXD can be used to make antibody drug conjugate such as Trastuzumab Deruxtecan (DS-8201a).
Application2
Application3
Dxd (Exatecan derivative for ADC) 是一种有效的DNA topoisomerase I抑制剂,IC50值为 0.31 μM,可用作靶作用于 HER2 的 抗体偶联药物 ADC (DS-8201a) 的有效载荷。
Dxd (Exatecan derivative for ADC) is a potentDNA topoisomerase Iinhibitor, with anIC50of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
警示图
危险性
危险性警示 Not available
安全声明 Not available
安全防护 Not available
备注 防止与皮肤接触,吸入
1: Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mol Cancer The
2: Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA top
3: Ogitani Y, Abe Y, Iguchi T, Yamaguchi J, Terauchi T, Kitamura M, Goto K, Goto M, Oitate M, Yukinaga H, Yabe Y, Nakada T, Masuda T, Morita K, Agatsuma T. Wide application of a novel topoisomerase I
4: Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epide
【1】.Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents